08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Institut National de la Sante et de la Recherche Medicale, ElsaLys Biotech deal

The institute granted ElsaLys exclusive, worldwide rights to CD160 for use in ophthalmology. The company and institute did not respond to inquiries. Last year, MABLife S.A.S (Evry, France) granted ElsaLys exclusive, worldwide rights to develop...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

MABLife, ElsaLys Biotech deal

MABLife granted ElsaLys exclusive worldwide rights to develop and commercialize MAT-302 . ElsaLys said it will develop two versions of the antibody, one to treat macular degeneration and one to treat B cell chronic lymphocytic...
07:00 , Mar 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD160

Cancer INDICATION: Cancer Mouse studies suggest CD160-positive NK cells could boost immunotherapy to help treat solid tumors. In mouse models of melanoma and lymphoma, CD160 knockout or depletion of NK cells increased tumor growth compared...
08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection; cytomegalovirus (CMV); Epstein-Barr virus (EBV); influenza virus CD160 In vitro studies suggest inhibiting CD160 could help treat viral infections by promoting T...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); hairy cell leukemia CD160; CD23; CD5 Human studies suggest CD160 expression could help diagnose CLL. In mature and immature B cells...
07:00 , Apr 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Age-related macular degeneration (AMD); cancer; diabetic retinopathy; retinopathy of prematurity CD160 Studies in mice suggest that an anti-CD160 mAb could help treat wet AMD, retinopathies...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV CD160; CD244 molecule, natural killer cell receptor 2B4 (CD244; 2B4); CD274 (PD-L1); cytotoxic T lymphocyte-associated protein 4 (CTLA4); lymphocyte-activation gene...
08:00 , Dec 18, 2008 |  BC Innovations  |  Targets & Mechanisms

Second wind for T cells

In the battle against HIV, HBV and HCV, all of which establish persistent infections that eventually wear down the antiviral cytotoxic T cell response, the odds for the immune system are poor. Three studies now...